Literature DB >> 30704797

Ten-year experience with multimodal treatment for acute phase Peyronie's disease: A real life clinical report.

L Gallo1, P Sarnacchiaro2.   

Abstract

OBJECTIVES: To present our experience with multimodal therapy for Peyronie's disease.
METHODS: Retrospective data were collected since 2008 to 2017. The following features were evaluated at baseline and after treatment: age, duration of disease, erectile function, erected penile curvature, and stretched penile length. All patients were offered the same protocol including: 12 intralesional verapamil injections, oral therapy (OT) ?L-arginine 2g once and pentoxifylline 400mg 3 times a day for 6 months?, and penile traction therapy. The adherence to each of the 3 components of multimodal treatment was evaluated.
RESULTS: One hundred and seventy-seven individuals were considered. Depending on the grade of adherence our survey was divided into 3 groups. Group 1: patients who only completed OT; group 2: men who accomplished OT and intralesional verapamil injections; group 3: patients who completed the entire protocol. Seventy-six, 45 and 56 men were assigned to group 1, 2 and 3 respectively. The mean age at the diagnosis was 59±8.4, 59.1±5.9 and 54.2±4.8 years, while the mean duration of the disease was 6.3±3.4, 4.8±2.9 and 3.9±3.1 months in group 1, 2 and 3. The erected penile curvature before and after treatment was 24.2±9 and 23.7±8.9° in group 1 (P<.36); 25.4±16.8 and 24.1±13.6° in group 2 (P<.34), and 34.3±17.9 and 26.1±17.2° in group 3 (P<.001).
CONCLUSIONS: OT alone was successful to block the progression of the disease. The add of intralesional verapamil injections to OT brought only mild improvements. The complete protocol significantly reduced erected penile curvature and improved erectile function.
Copyright © 2018 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Enfermedad de Peyronie; Intralesional verapamil injections; Inyecciones intralesionales de verapamilo; L-arginina; L-arginine; Multimodal therapy; Penile traction therapy; Pentoxifilina; Pentoxifylline; Peyronie's disease; Terapia de tracción del pene; Terapia multimodal

Mesh:

Substances:

Year:  2019        PMID: 30704797     DOI: 10.1016/j.acuro.2018.08.005

Source DB:  PubMed          Journal:  Actas Urol Esp (Engl Ed)        ISSN: 2173-5786


  4 in total

Review 1.  Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.

Authors:  Ayad Yousif; Caleb Natale; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2021-01-08       Impact factor: 3.092

2.  Adjuvant daily therapy with L-arginine 2,500 mg and tadalafil 5 mg increases efficacy and duration of benefits of low-intensity extracorporeal shock wave therapy for erectile dysfunction: A prospective, randomized, single-blinded study with 1-year follow-up.

Authors:  Luigi Gallo; Stefano Pecoraro; Pasquale Sarnacchiaro
Journal:  Investig Clin Urol       Date:  2022-01

3.  Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.

Authors:  Gianni Paulis; Giovanni De Giorgio
Journal:  J Med Case Rep       Date:  2022-10-08

Review 4.  The Use of Penile Traction Devices for Peyronie's Disease: Position Statements from the European Society for Sexual Medicine.

Authors:  Borja García-Gómez; Antonio Aversa; Manuel Alonso-Isa; Arie Parnham; Ege Can Serefoglu; Giovanni Corona; Carlo Bettocchi; Yacov Reisman; Marta Skrodzka; Javier Romero-Otero
Journal:  Sex Med       Date:  2021-07-15       Impact factor: 2.523

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.